Document Detail

Endothelin antagonists and heart failure.
MedLine Citation:
PMID:  11790297     Owner:  NLM     Status:  MEDLINE    
Chronic heart failure (CHF) is characterized by impaired left ventricular function, increased peripheral and pulmonary vascular resistance, reduced exercise tolerance, and dyspnea. Despite considerable progress in the treatment of CHF, especially in targeting activated neurohumoral systems, mortality in these patients remains high. Therefore, new treatment approaches are warranted. Endothelin-1 (ET-1) plasma levels are elevated in CHF and correlate with both hemodynamic severity and symptoms. Plasma levels of ET-1 are strong independent predictors of mortality in CHF. Combined ET(A/B) selective ET(A) receptor antagonists have been evaluated in patients with CHF showing impressive hemodynamic improvements. These results indicate that ET receptor antagonists indeed have a potential to improve hemodynamics, symptoms, and potentially prognosis in patients with CHF, which still carries a high mortality.
David Hürlimann; Frank Enseleit; Georg Noll; Thomas F Lüscher; Frank Ruschitzka
Related Documents :
17319797 - A double-blind randomized multicentre clinical trial to evaluate the efficacy and safet...
15802367 - Impact of aging on muscle blood flow in chronic heart failure.
9158167 - Dependence of peak oxygen uptake on oxygen transport capacity in chronic heart failure:...
17702647 - Excessive ventilation during early phase of exercise: a new predictor of poor long-term...
18325737 - The impact of exercise-induced changes in intraventricular dyssynchrony on functional i...
20622537 - The effect of exercise on mental health.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  4     ISSN:  1522-6417     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-01-15     Completed Date:  2002-04-10     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  85-92     Citation Subset:  IM    
Cardio Vascular Center, Cardiology, University Hospital, CH - 8091 Zürich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Endothelins / antagonists & inhibitors,  physiology*
Heart Failure / drug therapy,  physiopathology*
Hemodynamics / drug effects
Hypertension / drug therapy,  physiopathology*
Pyrrolidines / therapeutic use
Receptors, Endothelin / antagonists & inhibitors*,  physiology
Sulfonamides / therapeutic use
Reg. No./Substance:
0/A 127722; 0/Endothelins; 0/Pyrrolidines; 0/Receptors, Endothelin; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vasopeptidase inhibition: effective blood pressure control for vascular protection.
Next Document:  Directed proteomic analysis of the human nucleolus.